Effect of recombinant human brain natriuretic peptide combined with sacubitril and valsartan sodium tablets on the condition of patients with coronary atherosclerotic heart failure

Coronary atherosclerotic heart failure (CAHF) is a common clinical cardiovascular disease that seriously endangers human health. Combination of recombinant human brain natriuretic peptide and sacubitril-valsartan sodium tablets (rhBNP-SV) may have a positive effect on CAHF patients. However, there have been few research on this. In this study, 120 patients with CAHF were collected, 30 of them were used as control group and 90 patients were randomly divided into sacubitril-valsartan sodium tablet group, rhBNP group and combination group. The cardiac function-related indicators and serum mitochondrial coupling factor 6, ACE and others were examined. The levels of various cardiac function indexes in CAHF patients showed an upward trend and the increase was the most obvious in combination group. Patients in combination group had the longest walking distance within 6 minutes. Levels of the four groups of patients showed a downward trend and the intervention of rhBNP-VS showed the most significant decrease. Proportion of IFN-γ-positive lymphocytes in the total T lymphocytes gradually decreased with different interventions. Under rhBNP-SV intervention, ACE level in patients was significantly inhibited. The treatment of rhBNP-SV improved the exercise capacity of patients, reduced inflammatory response, and regulated ACE expression in patients with CAHF. Furthermore, it reduced the degree of vascular endothelial injury, inhibited the development of the disease, and ultimately enhanced the therapeutic effect to a large extent.